Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan

被引：0
|
作者：
Kondo, Tsunenori [1 ]
机构：
[1] Tokyo Womens Med Univ, Adachi Med Ctr, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2023年 / 30卷 / 09期
关键词：
D O I：
10.1111/iju.15256
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：777 / 778
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Harada, Ken-ichi
    Sato, Ryo
    Bando, Yukari
    Sano, Asuka
    Matsushita, Yuto
    Tamura, Keita
    Terakawa, Tomoaki
    Furukawa, Junya
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 772 - 777
  • [2] Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan
    Hara, Takuto
    Suzuki, Kotaro
    Okamura, Yasuyoshi
    Chiba, Koji
    Sato, Ryo
    Matsushita, Yuto
    Tamura, Keita
    Ishikawa, Gaku
    Otsuka, Atsushi
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (12) : 1931 - 1936
  • [3] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [5] Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States
    Zakharia, Yousef
    Vlahiotis, Anna
    Siu, Gordon
    Rao, Dharanija
    Teresi, Rosemary
    Eccleston, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [8] Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
    Beaulieu, Carissa
    Ghosh, Sunita
    Tajzler, Camilla
    Kirkpatrick, Mckayla
    Castonguay, Vincent
    Wood, Lori
    Graham, Jeffrey
    Soulieres, Denis
    Bansal, Rahul K.
    Heng, Daniel Yick Chin
    Finelli, Antonio
    Tanguay, Simon
    Lalani, Aly-Khan A.
    Bhindi, Bimal
    Bjarnason, Georg A.
    Breau, Rodney H.
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 382 - 382
  • [9] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
    Chubenko, Viacheslav
    Baklanova, Olga
    Kalpinskiy, Alexey
    Safina, Sufiia
    Lebedinets, Andrey
    Shkurat, Alexey
    Parsadanova, Elvira
    Turganova, Maria
    Petkau, Vladislav
    Tovbik, Natalya
    Tkacheva, Elena
    Anzhiganova, Yulia
    Novikova, Olga
    Bragina, Varvara
    Zukov, Ruslan
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 117 - 117
12345